ANDA 203845, held by Cadila Pharms Ltd. Hydralazine Hydrochloride.
As of Nov 16, 2026, ANDA 203845 (Hydralazine Hydrochloride), held by Cadila Pharms Ltd, was first approved by FDA on Sep 18, 2014, with 2 approved supplements and 0 published complete response letters.
INDICATIONS & USAGE Essential hypertension, alone or as an adjunct.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 18, 2014 | Original application | Approved | None posted |
| Hydralazine Hydrochloride25MG · tablet;oral | Hydralazine Hydrochloride | Rx |
| Hydralazine Hydrochloride50MG · tablet;oral | Hydralazine Hydrochloride | Rx |
| Hydralazine Hydrochloride100MG · tablet;oral | Hydralazine Hydrochloride | Rx |
| Oct 30, 2018 | Supplement 1Labeling · Standard review | Approved | None posted |
| Oct 30, 2018 | Supplement 2Manufacturing | Approved | None posted |
| Sep 18, 2014 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters